Differences in clinical outcomes in keratitis due to fungus and bacteria.
作者信息
Prajna N Venkatesh, Srinivasan Muthiah, Lalitha Prajna, Krishnan Tiruvengada, Rajaraman Revathi, Ravindran Meenakshi, Mascarenhas Jeena, Oldenburg Catherine E, Ray Kathryn J, McLeod Stephen D, Acharya Nisha R, Lietman Thomas M
出版信息
JAMA Ophthalmol. 2013 Aug;131(8):1088-9. doi: 10.1001/jamaophthalmol.2013.1612.
Abstract
摘要
相似文献
1
Differences in clinical outcomes in keratitis due to fungus and bacteria.真菌性角膜炎与细菌性角膜炎临床结局的差异。
JAMA Ophthalmol. 2013 Aug;131(8):1088-9. doi: 10.1001/jamaophthalmol.2013.1612.
2
Clinical aspects and prognosis of mixed microbial (bacterial and fungal) keratitis.混合微生物（细菌和真菌）角膜炎的临床特点和预后。
Cornea. 2011 Apr;30(4):409-13. doi: 10.1097/ICO.0b013e3181f23704.
3
Comparison of culture-negative and culture-positive microbial keratitis: cause of culture negativity, clinical features and final outcome.培养阴性与培养阳性微生物性角膜炎的比较：培养阴性的原因、临床特征及最终结局
Br J Ophthalmol. 2015 Nov;99(11):1498-502. doi: 10.1136/bjophthalmol-2014-306414. Epub 2015 Apr 24.
4
Use of voriconazole in fungal keratitis.伏立康唑在真菌性角膜炎中的应用。
J Cataract Refract Surg. 2008 Feb;34(2):183-4. doi: 10.1016/j.jcrs.2007.09.031.
5
The Asia Cornea Society Infectious Keratitis Study: A Prospective Multicenter Study of Infectious Keratitis in Asia.亚洲角膜学会感染性角膜炎研究：亚洲感染性角膜炎的前瞻性多中心研究。
Am J Ophthalmol. 2018 Nov;195:161-170. doi: 10.1016/j.ajo.2018.07.040. Epub 2018 Aug 9.
6
The Prognostic Value of Persistent Culture Positivity in Fungal Keratitis in the Mycotic Antimicrobial Localized Injection Trial.真菌性角膜炎抗真菌药物局部注射治疗试验中持续真菌培养阳性的预后价值。
Am J Ophthalmol. 2020 Jul;215:1-7. doi: 10.1016/j.ajo.2020.02.021. Epub 2020 Apr 28.
7
Update on the Management of Infectious Keratitis.感染性角膜炎的治疗进展
Ophthalmology. 2017 Nov;124(11):1678-1689. doi: 10.1016/j.ophtha.2017.05.012. Epub 2017 Sep 21.
8
Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts.紫外线A/核黄素角膜交联术治疗与角膜溶解相关的感染性角膜炎
Cornea. 2008 Jun;27(5):590-4. doi: 10.1097/ICO.0b013e318169d698.
9
Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.纳他霉素和伏立康唑的体外药敏与真菌性角膜炎临床结局之间的关联
Ophthalmology. 2014 Aug;121(8):1495-500.e1. doi: 10.1016/j.ophtha.2014.03.004. Epub 2014 Apr 16.
10
Etiologic diagnosis of corneal ulceration at a tertiary eye center in Kathmandu, Nepal.尼泊尔加德满都一家三级眼科中心角膜溃疡的病因学诊断。
Cornea. 2010 Dec;29(12):1380-5. doi: 10.1097/ICO.0b013e3181d92881.
引用本文的文献
1
Comparison of Recurrent and Naïve Keratitis in a Cohort of 1303 Patients.1303例患者复发性与原发性角膜炎的比较
J Clin Med. 2025 May 27;14(11):3760. doi: 10.3390/jcm14113760.
2
Pathology-inspired collagen-binding thermosensitive micelle drops enable prolonged and efficient treatment of fungal keratitis.受病理学启发的胶原结合热敏胶束滴眼液可实现真菌性角膜炎的长期有效治疗。
Bioact Mater. 2025 Apr 22;50:396-413. doi: 10.1016/j.bioactmat.2025.04.011. eCollection 2025 Aug.
3
Phaeoacremonium iranianum - a new corneal pathogen.伊朗拟顶孢霉——一种新的角膜病原体。
BMC Ophthalmol. 2025 Apr 22;25(1):230. doi: 10.1186/s12886-025-04064-1.
4
Rapid Point-of-Care Identification of Aspergillus Species in Microbial Keratitis.微生物角膜炎中曲霉菌种的即时现场快速检测。
JAMA Ophthalmol. 2023 Oct 1;141(10):966-973. doi: 10.1001/jamaophthalmol.2023.4214.
5
Oral voriconazole monotherapy for fungal keratitis: efficacy, safety, and factors associated with outcomes.口服伏立康唑单药治疗真菌性角膜炎：疗效、安全性及与预后相关的因素。
Front Med (Lausanne). 2023 May 11;10:1174264. doi: 10.3389/fmed.2023.1174264. eCollection 2023.
6
Evaluation of liposomal amphotericin B for the treatment of fungal keratitis in a tertiary eye care hospital.评价两性霉素 B 脂质体治疗三级眼科医院真菌性角膜炎的效果。
Indian J Ophthalmol. 2023 Feb;71(2):518-523. doi: 10.4103/ijo.IJO_1474_22.
7
The Case for Fungal Keratitis to Be Accepted as a Neglected Tropical Disease.将真菌性角膜炎认定为被忽视的热带病的理由。
J Fungi (Basel). 2022 Oct 5;8(10):1047. doi: 10.3390/jof8101047.
8
Profiling of the Conjunctival Bacterial Microbiota Reveals the Feasibility of Utilizing a Microbiome-Based Machine Learning Model to Differentially Diagnose Microbial Keratitis and the Core Components of the Conjunctival Bacterial Interaction Network.结膜细菌微生物组分析揭示了利用基于微生物组的机器学习模型对微生物性角膜炎进行鉴别诊断的可行性，以及结膜细菌相互作用网络的核心成分。
Front Cell Infect Microbiol. 2022 Apr 26;12:860370. doi: 10.3389/fcimb.2022.860370. eCollection 2022.
9
Thermosensitive Tri-Block Polymer Nanoparticle-Hydrogel Composites as Payloads of Natamycin for Antifungal Therapy Against .热敏性三嵌段聚合物纳米颗粒-水凝胶复合材料作为纳他霉素的载体用于抗真菌治疗
Int J Nanomedicine. 2022 Mar 28;17:1463-1478. doi: 10.2147/IJN.S332127. eCollection 2022.
10
Comparative study on costs incurred for treatment of patients with bacterial and fungal keratitis - A retrospective analysis.细菌和真菌性角膜炎患者治疗费用的对比研究——回顾性分析。
Indian J Ophthalmol. 2022 Apr;70(4):1191-1195. doi: 10.4103/ijo.IJO_2176_21.
本文引用的文献
1
Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).用于细菌性角膜炎的皮质类固醇：角膜溃疡类固醇试验（SCUT）。
Arch Ophthalmol. 2012 Feb;130(2):143-50. doi: 10.1001/archophthalmol.2011.315. Epub 2011 Oct 10.
2
The steroids for corneal ulcers trial: study design and baseline characteristics.角膜溃疡类固醇试验：研究设计与基线特征
Arch Ophthalmol. 2012 Feb;130(2):151-7. doi: 10.1001/archophthalmol.2011.303. Epub 2011 Oct 10.
3
Comparison of natamycin and voriconazole for the treatment of fungal keratitis.那他霉素与伏立康唑治疗真菌性角膜炎的比较。
Arch Ophthalmol. 2010 Jun;128(6):672-8. doi: 10.1001/archophthalmol.2010.102.
4
Risk factors for treatment outcome in fungal keratitis.真菌性角膜炎治疗结果的危险因素。
Ophthalmology. 2006 Apr;113(4):526-30. doi: 10.1016/j.ophtha.2005.10.063.
5
Risk factors and clinical outcomes between fungal and bacterial keratitis: a comparative study.真菌性与细菌性角膜炎的危险因素及临床结局：一项对比研究。
CLAO J. 1997 Oct;23(4):275-81.
Zotero 插件